Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN

Abeona Therapeutics (ABEO) and Children’s Hospital Colorado announced activation of Children’s Colorado as the newest Qualified Treatment Center, QTC, for ZEVASKYN gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. Children’s Colorado in Aurora, CO, has completed QTC start-up activities enabling it to begin patient identification for scheduling of ZEVASKYN treatment.